Dendritic cell therapy (DC therapy) is a regulated form of personalized cancer immunotherapy that uses the body’s immune cells to recognize and destroy cancer cells. In Europe, it falls under the Advanced Therapy Medicinal Products (ATMP) framework established by the European Medicines Agency (EMA) — a system that ensures quality, safety, and efficacy for all cell-based medicinal products.
Yet, despite EU-wide recognition, not all member states have implemented this framework to the same extent. Here’s how the regulation works — and why countries like France are lagging behind in full ratification.
Since 2007, the EMA has provided a clear regulatory foundation for cell-based therapies, including dendritic cell immunotherapies. According to multiple official EMA scientific opinions, dendritic cell products qualify as somatic cell therapy medicinal products under Regulation (EC) No. 1394/2007, as they consist of human cells that have been substantially modified to exert a therapeutic immunological effect
EMA2015-556392 – DC – Treatment…
This classification means that dendritic cell therapies must undergo rigorous assessment — just like any other pharmaceutical product — to prove safety, purity, and clinical efficacy before authorization for use in patients. Dendritic cells are a type of antigen-presenting cell that play a critical role in the immune system. They are responsible for capturing antigens (foreign substances that trigger an immune response) and presenting them to T-cells, which then mount a targeted attack against the invaders. In the context of cancer, Dendritic Cell Therapy involves extracting these cells from a patient, loading them with tumor antigens, and then reintroducing them into the patient’s body to stimulate a robust immune response against the cancer cells.
Over the past decade, the EMA has granted Orphan Drug Designation to several dendritic cell-based therapies for rare and serious diseases, confirming their legitimacy and scientific value. Examples include:
EMA2013-96767 – DC – Treatment …
EMA2013-400483 – DC – Treatment…
EMA2014-67860 – DC – Treatment …
EMA2015-17038 – DC – Treatment …
EMA2013-50963 – DC – Treatment …
EMA2015-556392 – DC – Treatment…
Each of these designations is backed by scientific data showing that dendritic cell-based immunotherapies can induce specific immune responses and potentially improve long-term outcomes for patients where conventional therapies fail.
Although the ATMP regulation applies to the entire European Union, national implementation differs. Some countries — including France — have not yet fully transposed all aspects of the EU directive into domestic pharmaceutical law.
Consequently, dendritic cell therapy cannot be offered under identical clinical or regulatory conditions in every country. For example, while Germany, the Netherlands, and Belgium have integrated the full ATMP framework and allow these therapies under clinical trials, hospital exemptions, or compassionate-use programs, others maintain more restrictive access.
This discrepancy creates unequal availability of regulated immunotherapies within the European market, even though the scientific and legal foundation is consistent across the EU.
Dendritic cell therapy is officially recognized and regulated under EU law as an Advanced Therapy Medicinal Product (ATMP). It is not experimental or unregulated — it is a legitimate, science-based approach validated by the European Medicines Agency.
However, patient access depends on the national adoption of EU regulatory standards.
Clinics providing such therapies must operate under certified quality systems, ethical oversight, and official authorization in accordance with EMA and national agency requirements.
European Medicines Agency (EMA) – Scientific and Public Summaries on Dendritic Cell-Based Therapies (2013–2015):
EMA/556392/2015, EMA/400483/2013, EMA/50963/2013, EMA/96767/2013, EMA/67860/2014, EMA/17038/2015
REGISTERED ADDRESS:
Immunyo Ltd
Kincora Ave 35
Clontarf
Dublin 3
Ireland
International
For Germany, Austria and Switzerland
